Table 1 The clinical features of JDM complicated with MAS
Patient number | Study (year) | Patient/ gender/age | Skin lesions | MS, and CK level (U/L) | Arthritis | ILD | MSA | From JDM onset to MAS |
|---|---|---|---|---|---|---|---|---|
1 | Kobayashi et al. (2000) [5] | 1/M/14 | Gottron’s papules and heliotrope eruption | Weakness; CK 26U/L | Yes | Yes | ND | 3 months |
2 | Sterba et al. (2004) [6] | 1/M/12 | ND | ND | ND | ND | ND | ND |
3 | Kobayashi et al. (2006) [7] | 1/F/10 | Gottron’s papules and heliotrope eruption | Weakness; CK 579 U/L | No | Yes | ND | 2 weeks |
4 | Yajima et al. (2008) [8] | 1/M/16 ADM | ND | Normal | Yes | Yes | ND | Active phase of DM |
5 | Bustos et al. (2012) [9] | 1/M/7 | Heliotrope sign and facial edema | Weakness; CK 16,353 U/L | No | ND | ND | 4 weeks |
6 | Wang et al. (2013) [10] | 1/M/15, | Heliotrope sign and facial edema | Weakness; CK 3325 U/L | No | No | ND | 2 weeks |
7 | Yamashita et al. (2013) [11] | 1/F/17 | Heliotrope, Gottron’s sign, and nail-fold lesions | Weakness; CK 1094 U/L | Yes | Yes | No | 3 months |
8 | Lilleby et al. (2014) [12] | 1/M/12 | Facial erythema and facial swelling | Weakness; CK 14,000 U/L | No | Yes | ND | 5 weeks |
9 | Ye et al. (2014) [13] | 1/M/16 | Heliotrope rash and facial swelling | Weakness; CK 1071 U/L | No | Yes | No | 6 weeks |
10 | Poddighe et al. (2014) [14] | 1/F/13 ADM | Heliotrope, Gottron’s rash, and peri-orbital edema | Normal | Yes | Yes | ND | 3 months |
11 | Önen et al. (2014) [15] | 1/F/12 | Heliotrope rash | Weakness; CK 25 U/L | No | No | ND | 6 months |
12 | Wakiguchi et al. (2015) [16] | 1/F/4 | Heliotrope rash and Gottron’s sign | Weakness; CK 40 U/L | No | Yes | MDA5 | 3 months |
13 | Teshigawara et al. (2016) [17] | 1/M/17 | Heliotrope eruption | Myalgia; CK 1869 U/L | No | No | No | 6 months |
14 | Deschamps et al. (2018) [18] | 1/F/17 | Right facial swelling | Weakness; CK 4265 U/L | No | No | NXP2 | 5 weeks |
15 | Stewart JA et al. (2022) [19] | 1/F/14 | Ulcerative lesions on the dorsum of the hands | Weakness; CK 217 U/L | Yes | Yes | MDA5 | 3 months |
16 | Mouri M et al. (2022) [20] | 1/M/5 | Heliotrope rash and Gottron’s sign | Weakness; CK 2511 U/L | Yes | No | NXP2 | 2 weeks |
17 | Jagwani H et al. (2022) [21] | 1/M/11 | Heliotrope sign | Weakness; elevated CK level | ND | No | No | 4 weeks |
18 | Our case | 1/F/15 | Heliotrope rash and mild edema on upper arm | Weakness, CK 2914 U/L | No | No | NXP2 | 3 months |